Argentina and Mexico to produce AstraZeneca Covid-19 vaccine

▴ Argentina and Mexico to produce AstraZeneca Covid-19 vaccine
Argentina and Mexico will produce the AstraZeneca COVID-19 vaccine for most of Latin America

Argentina and Mexico will produce the AstraZeneca COVID-19 vaccine for most of Latin America, Argentine President Alberto Fernandez said on Wednesday after a meeting with company executives involved in the project.

Argentina's President Alberto Fernandez gestures during the announcement that Argentina and Mexico will produce and distribute an experimental coronavirus vaccine, at the Olivos Presidential residence, in Buenos Aires, Argentina August 12, 2020.

An agreement signed between British pharmaceutical company AstraZeneca and the biotechnology company mAbxience of the INSUD Group includes transfer of technology to initially produce 150 million doses of the vaccine to supply all of Latin America with the exception of Brazil, the Argentine government said.

“Latin American production will be handled in Argentina and Mexico and that will allow timely and efficient access for all countries in the region,” Fernandez said.

Mexican Foreign Minister Marcelo Ebrard said later on Twitter that the deal had been pushed by Fernandez and Mexican President Andres Manuel Lopez Obrador. He said output of the vaccine could extend to 250 million doses.

AstraZeneca, Britain’s second-largest drugmaker, has long operations in Argentina. The company signed a deal with the foundation of Mexican billionaire Carlos Slim for the production of the vaccine, which is expected to be delivered in the first half of 2021, pending Phase III studies and regulatory approvals.

Mexico would provide more details on Thursday, said Ebrard, who thanked the Slim Foundation for financing production.

Arturo Elias, Slim’s spokesman, said a “very significant” sum was being invested in the scheme, without giving a figure.

“There’s a major economic commitment regardless of whether the vaccine works,” he told Reuters, noting that the foundation would start work immediately.

Fernandez said the deal “gives Argentina the peace of mind of being able to have the vaccine when required and at a reasonable price.”

Argentina, which has passed 5,000 coronavirus fatalities, posted a record daily number of COVID-19 infections on Wednesday with 7,663 new cases. Mexico has registered nearly 55,000 deaths and almost half a million cases.

Worldwide coronavirus cases have surpassed 20.4 million, according to the Johns Hopkins University. More than 12.7 million have recovered, and more than 745,000 have died. Back at home, India's coronavirus case tally has spiked by 66,999 cases in the last 24 hours. As per the latest data issued by the Ministry of Health and Family Welfare (MoHFW), India's COVID-19 case tally has surged to 23,96,638 out of which, 16,95,982 people have recovered while 6,53,622 are still suffering from the virus. COVID-19 death toll in India has gone past 47,000 with a single day jump of 942.ack at home, 

Story Courtesy: www.reuters.com 

Tags : #ArgentinaCovidNewsAug13 #AlbertoFernandez #MexicoCovidNewsAug13 #JohnHopkins #AstraZenecaNesAug13 #AstraZeneca #LatestPharmaNewsAug13 #LatestPharmaUpdateAug13 #mAbxience #InsudGroup

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Children in Cities Exposed to Elevated Lead Levels: Study Reveals Urgent Health ConcernApril 20, 2024
Biocon Ventures into Weight-Loss Drug Market with Semaglutide DevelopmentApril 20, 2024
Innovative AI Assistance Empowers Moscow Doctors to Detect Cervical Spine Issues through MRI ScansApril 20, 2024
Air India Express ties up with AISATS for AeroWash Automated Aircraft Exterior Cleanings April 19, 2024
IndoSup raises strategic funding led by CCI group promoters Naresh Sharma and Satish Sharma; investors include Yatra.com’s Rohan Mittal April 19, 2024
10 compelling reasons why choosing right media platform Is important in healthcareApril 19, 2024
Protecting Public Health: Proposed Guidelines for Pharmaceutical Product DistributionApril 19, 2024
What is Haemophilia: A Genetic Bleeding Disorder that has Affected 1,36,000 IndiansApril 19, 2024
Climate Change and Stroke Risk: Exploring the Impact of Temperature Fluctuations on Your Body April 19, 2024
The Extension and Benefits of ABHA Linking with CGHS Beneficiary ID: What You Need to KnowApril 19, 2024
Mental Health Issues Impact Studies in 3 out 4 Female Students: PeakMind StudyApril 18, 2024
Atal Incubation Centre – Centre for Cellular and Molecular Biology (AIC-CCMB) signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India April 18, 2024
MiracleMe Introduces Revolutionary Orally Dissolving Plant-Based Nutrition ProductsApril 18, 2024
South Indian Bank signs MOU with Ashok Leyland Limited for Dealer FinancingApril 18, 2024
Serum Institute of India Partners with Oxford University to Develop Meningitis-B VaccineApril 18, 2024
Ethical Concerns Arise: Nestlé Accused of Adding Sugar and Honey to Infant Formula and Breakfast Cereals in Low-Income CountriesApril 18, 2024
Empowering India's Youth: IG Drones & AASSC Launch Drone Skill Program, to Upskill 10M YouthApril 17, 2024
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment TechnologyApril 17, 2024
Top 5 online learning platform for learnersApril 17, 2024
Broad-Spectrum RNA Vaccine Breakthrough for Enhanced Virus ProtectionApril 17, 2024